信达生物股东将股票存入香港上海汇丰银行 存仓市值45.98亿港元

Core Viewpoint - The latest data from the Hong Kong Stock Exchange indicates that on December 24, shareholders of Innovent Biologics (01801) deposited shares worth HKD 45.98 billion, representing 3.31% of the total [1] Group 1: Company Developments - UBS reported that six new products from Innovent Biologics and a new indication for Tyvyt (sintilimab) have been included in the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) [1] - Innovent Biologics has officially been included in the Hang Seng Index [1] Group 2: Analyst Ratings - UBS maintains a "Buy" rating for Innovent Biologics with a target price of HKD 137.4 [1]